Immunoglobulin G1, Anti-(Mesothelin) (Human-Mouse Monoclonal Morab-009 Heavy Chain), Disulfide With Human-Mouse Monoclonal Morab-009 .Kappa.-Chain, Dimer
Non-Small Cell Lung Carcinoma
Explore 1,125 assets in Non-Small Cell Lung Carcinoma →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Morphotek
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
43High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01521325CT.gov A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers | — | Completed | — | — | — |
NCT01413451CT.gov Amatuximab for High Mesothelin Cancers | — | Terminated | — | — | — |
NCT00325494CT.gov A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1, Anti-(Mesothelin) (Human-Mouse Monoclonal Morab-009 Heavy Chain), Disulfide With Human-Mouse Monoclonal Morab-009 .Kappa.-Chain, Dimer (this asset) | Morphotek | P1 | CCC · 48 |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Endostatin | Henan Cancer Hospital | P4 | BBB |
| Zorifertinib | Alpha Biopharma (Jiangsu) Co., Ltd. | P2/3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Vinorelbine Ditartrate | Intergroupe Francophone de Cancerologie Thoracique | P4 | BB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Immunoglobulin G1, Anti-(Mesothelin) (Human-Mouse Monoclonal Morab-009 Heavy Chain), Disulfide With Human-Mouse Monoclonal Morab-009 .Kappa.-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mesothelioma | — | P1 | CCC · 53 |
| Pancreatic Neoplasm | — | P2 | CCC · 49 |
| Ovarian Cancer | — | P1 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1, Anti-(Mesothelin) (Human-Mouse Monoclonal Morab-009 Heavy Chain), Disulfide With Human-Mouse Monoclonal Morab-009 .Kappa.-Chain, Dimer in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-mesothelin-human-mouse-monoclonal-morab-009-heavy-chain-disulfide-with-human-mouse-monoclonal-morab-009-kappa-chain-dimer-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →